Madrigal Pharmaceuticals Director Baker Bros. Advisors LP Buys $35M of Stock
Baker Bros. Advisors LP, Director, bought 91,806 shares of Madrigal Pharmaceuticals, Inc. at $366.99 to $396.61 a share (average $381.49) in 5 transactions, worth $35M in total between Nov 4, 2026 and Nov 6, 2026. Shares held after the trade: 2,040,682 (+0.1%).
Madrigal Pharmaceuticals General Counsel Shannon T. Kelley Sells $431K of Stock
Shannon T. Kelley, General Counsel, sold 1,077 shares of Madrigal Pharmaceuticals, Inc. at $400.00 a share, worth $431K in total on Nov 6, 2026. Shares held after the trade: 10,397 (-9.4%).
Madrigal Pharmaceuticals reported a significant increase in net product revenue to $431.3 million for the third quarter of 2026, resulting in a quarterly net income of $55.4 million compared to a net loss in the prior year. For the nine months ended September 30, 2026, the company maintained a net loss of $96.9 million as it continues to scale commercial operations for Rezdiffra.
Madrigal Pharmaceuticals reported third-quarter 2026 financial results, highlighted by Rezdiffra net sales of $431.3 million and the achievement of its first quarter of profitability. The company also announced that Rezdiffra reached blockbuster status with year-to-date net sales of $1.1 billion and plans to initiate a new Phase 3 outcomes trial, MAESTRO-CSPH, in the first half of 2027.
“Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market.”
Bill Sibold, Chief Executive Officer of Madrigal
“Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH.”